Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Table 2 Subjective measures assessed by visual analogue scale (0–100 mm)

Parameters	Baseline (n = 16)	6 weeks (n = 15)	10 weeks (n = 13)	18 weeks (n = 14)	32 weeks (n = 11)
Fatigue	55 ± 21	46 ± 30	44 ± 28	45^a ± 22	41^a ± 29
Pain	49 ± 28	31 ± 32	32 ± 29	39 ± 25	34 ± 26
Patient assessment^b	62 ± 29	38^a ± 30	49 ± 23	48^a ± 31	40^a ± 28
Physician assessment^c	56 ± 16	30^a ± 22	36^a ± 14	31^a ± 20	26^a ± 12

Results are given in mean ± standard deviation. ^aDenotes statistical significance of the observed median change-from-baseline value with P ≤ 0.05 by Wilcoxon signed rank test. ^bPatient self-assessment of overall well-being. ^cPhysician global assessment of patient's overall well-being.

ISSN: 1478-6362